Search Protocols under revision. Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapyHematologic NeoplasmsSolid TumorsProtocol groupPlasma cell neoplasmsSarcomasTransplantationDiseaseEwing SarcomaMultiple MyelomaStem Cell mobilizationStem Cell Transplantation, AutologousSubgroupICD10C40.-C41.-C90.-C90.0-Z94.80MeSHHematopoietic Stem Cell MobilizationPlasmacytomaSarcoma, EwingTransplantation, AutologousSequenceAURIGA: DRTM1800/LENA10, MM, maint. according to ASCT, C1-2 (PID2796) -|- C3-6 (PID2797) -|- C7+ (PID2798)EWING 2012 Arm A VIDEEWING 2012 Arm B VDC/IEIFM 2009/DETERMINATION: BORT1.3/LENA25/DEXA20, Ind., MM (PID1036) -|- cons. after ASCT (PID1040) or cons. without ASCT (PID1037) -|- maint. after ASCT (PID891) or maint. (PID2181)ChemotherapyChemo-substanceBortezomibCyclophosphamideDaratumumabDexamethasoneLenalidomideChemo-substanceBortezomibCyclophosphamideDaratumumabDexamethasoneLenalidomideChemo-substanceBortezomibCyclophosphamideDaratumumabDexamethasoneLenalidomideChemo-substanceBortezomibCyclophosphamideDaratumumabDexamethasoneLenalidomideNo. Substances123 RadiotherapySupportive therapySupportive substanceAcetylsalicylic acidAciclovirBalanced Crystalloid SolutionBusulfanCiprofloxacinCotrimoxazoleDalteparinDexamethasoneDimetindenFilgrastimFosaprepitantFurosemideGranisetronLevetiracetamMelphalanMesnaMontelukastPantoprazoleParacetamolPlerixaforPrednisoloneUrsodeoxycholic acidValaciclovirSupportive substanceAcetylsalicylic acidAciclovirBalanced Crystalloid SolutionBusulfanCiprofloxacinCotrimoxazoleDalteparinDexamethasoneDimetindenFilgrastimFosaprepitantFurosemideGranisetronLevetiracetamMelphalanMesnaMontelukastPantoprazoleParacetamolPlerixaforPrednisoloneUrsodeoxycholic acidValaciclovirSupportive substanceAcetylsalicylic acidAciclovirBalanced Crystalloid SolutionBusulfanCiprofloxacinCotrimoxazoleDalteparinDexamethasoneDimetindenFilgrastimFosaprepitantFurosemideGranisetronLevetiracetamMelphalanMesnaMontelukastPantoprazoleParacetamolPlerixaforPrednisoloneUrsodeoxycholic acidValaciclovirSupportive substanceAcetylsalicylic acidAciclovirBalanced Crystalloid SolutionBusulfanCiprofloxacinCotrimoxazoleDalteparinDexamethasoneDimetindenFilgrastimFosaprepitantFurosemideGranisetronLevetiracetamMelphalanMesnaMontelukastPantoprazoleParacetamolPlerixaforPrednisoloneUrsodeoxycholic acidValaciclovirNo. Substances456811Protocol classificationTherapy classificationalternativecurrent standardstudy analogIntensityhigh doseHochdosis, bei autologer SZTStandard doseTherapy indicationFirst lineseveral possibleTherapy phaseautologous stem cell transplantationConsolidationMaintenanceTherapy intentioncurativedisease controlRisksAnemia Hb below 8g/dlArthalgiaConstipationCOVID-19 infectionDiarrheaEmetogenicityEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)FatigueFebrile NeutropeniaHeadacheHypertensionHypokalemiaInfectionsLymphopeniaNeuropathyNeutropeniaPneumoniaRashThrombocytopenia below 50 000/µlThromboembolic EventUpper Respiratory Tract Infection only studiesPublicationAuthorAnderton JAttal MBadros AZGoldschmidt HMcCarthy PRichardson PDiseaseAuto-SZT beim MMEwing Sarkom, ErstlinieMM Stadium II und III, 18 - 65 Jahre, ECOG 0-3 (3 nur wenn durch Myelom bedingt), ErstlinieMultiples Myelom, ECOG 0-1multiples Myelom, Erstdiagnose nach Induktionstherapie und autologer Transplantation, ECOG 0-1Multiples Myelom, nach Induktionstherapie und autologer Transplantation, VGPR, MRD+, ECOG 0-2neudiagnostiziertes multiples Myelom, < 65 JahreOriginBMT Program, Roswell Park Cancer Institute, Buffalo, NY, CALGB 100104Euro Ewing 2012 protocolHOVON-65/GMMG-HD4 StudieIFm2009 / Determination trialInstitut Universitaire du Cancer de Toulouse-Oncopole and Service d'Epidemiologie, Centre Hospitalier et Universitaire de Toulouse, Toulouse, FranceInstitut Universitaire du Cancer de Toulouse-Oncopole and Service d’Epidémiologie, Toulouse, IFM 2009 StudyUniversity of Maryland, Baltimore, Maryland, United States, AURIGA studyProtokolle in Überarbeitung 9 protocols foundAURIGA - Daratumumab 1800 / Lenalidomide 10, multiple myeloma, maintenance after Stem Cell Transplantation, Autologous, Cycle 1-2 (PID2796 V1.1)AURIGA - Daratumumab 1800 / Lenalidomide 10, Multiple Myeloma, maintenance after Stem Cell Transplantation, Autologous, Cycle 3-6 (PID2797 V1.1)AURIGA - Daratumumab 1800 / Lenalidomide 10, Multiple Myeloma, maintenance after Stem Cell Transplantation, Autologous, Cycle 7+ (PID2798 V1.1)Bortezomib 1.3 / Lenalidomide 25 / Dexamethasone 10, Multiple Myeloma, Consolidation after Autologous Stem Cell Transplantation. (PID1040 V1.2)Revision: Busulfan 0.8 / Melphalan 140, Autologous Stem Cell Transplantation (PID571 V1.2)High dose Cyclophosphamide 2000 for stem cell mobilization, Multiple Myeloma (PID535 V1.0.1)Lenalidomide 10, Multiple Myeloma, maintenance (PID2181 V1.0)Lenalidomide 10, Multiple Myeloma, Maintenance after Autologous Stem Cell Transplantation, Autologous (PID891 V1.1)Revision: Melphalan 100, Multiple Myeloma, Autologous Stem Cell Transplantation (PID528 V2.3)
